We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
Progress against malaria has stalled, and the disease remains a significant threat to billions of people despite the expensive, decades-long efforts to contain it. In an encouraging development, MORU reported complete success in curing hundreds of patients in Southeast Asia with new three-drug combinations mixing fast-acting artemisinin with two longer-lasting drugs. It it hoped that triple therapy should become the standard for malaria treatment.
On 6-7 May in Zanzibar, Tanzania, the final investigators’ meeting of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project brought together 35 investigators from participating institutions in Bangladesh, Cambodia, Guinea, Nigeria, Niger, Tanzania, The Gambia, Rwanda, Singapore, and MORU, along with key partners from Fosun Pharma, Medicines for Malaria Venture (MMV), the WHO Global Malaria Programme, and the UK Foreign, Commonwealth and Development Office (FCDO), which funded the project over the past seven years.
©
Jane Hahn for The Washington Post, via Getty Images
